IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

BORCHERDING, et al.

Examiner:

Not Yet Assigned

Art Unit:

Sigi

Not Yet Assigned

.

Application No.: Filed Herewith

Filed:

October 2, 2003

Title:

ACYL AND SULFONYL

DERIVATIVES OF 6,9-

DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES

AND THEIR USE AS

ANTIPROLIFERATIVE AGENTS

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Cortanissioner for Patents, P.O. Box 1450, Alexandria, VA 2313-1450, on

2 October 2003

DUS PIECLE, S

EL 964841904 US Mail No.

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821 (c) and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same.

Respectfully submitted

Michael Schmelzer, Reg. No. 43,093

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800

Telephone (908) 231-4797 Telefax (908) 231-2626

Aventis Docket No. USA3960 US CNT